APT-101

APT-101 is an orally bioavailable small molecule that acts as a selective and potent agonist of the apelin receptor (APJ). It is being developed as a novel anti-fibrotic and anti-inflammatory agent for fibrotic lung diseases, including systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF). By activating APJ, APT-101 works upstream to normalize key pathways involved in vascular endothelial cell health, repair damaged pulmonary vasculature, reduce inflammation, and limit fibrosis. Preclinical studies have shown that APT-101 reduces fibrosis and inflammation in animal models of SSc and IPF. The drug is currently in preclinical/IND application stages. APIE Therapeutics is developing this compound under license from RTI International[1][5][6][7][8].

Other names

(S)-3-(1-Cyclopentyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrazole-3-carboxamido)-5-(3,3-difluoropiperidin-1-yl)pentanoic acidapt-101 hydrochlorideapt101 hydrochlorideapt 101 hydrochloride